RECURSION PHARMACEUTICALS, INC. (RXRX) — Total Liabilities
| Fiscal Year | Total Liabilities | Change YoY |
|---|---|---|
| 2025 | $343.26M | -17.0% |
| 2024 | $413.82M | +117.5% |
| 2023 | $190.26M | -11.7% |
| 2022 | $215.48M | +219.7% |
| 2021 | $67.41M | +19.2% |
| 2020 | $56.56M | — |
| Fiscal Year | Total Liabilities | Change YoY |
|---|---|---|
| 2025 | $343.26M | -17.0% |
| 2024 | $413.82M | +117.5% |
| 2023 | $190.26M | -11.7% |
| 2022 | $215.48M | +219.7% |
| 2021 | $67.41M | +19.2% |
| 2020 | $56.56M | — |